FDA Approves First-of-its-kind Device to Treat Heart Failure Patients

FDA approved an implantable device sold by Impulse Dynamics to treat patients with Class III moderate to severe heart failure who are not suitable for cardiac resynchronization therapy (CRT).

Food and Drug Administration (FDA) of the US has approved a new device called the Optimizer Smart system for treating patients with chronic, life-threatening heart failure. This device addresses the unmet need of patients who are not able to receive treatment with other heart failure devices.

The Optimizer Smart system is comprised of several components, including an implantable pulse generator, battery charger, programmer and software. The pulse generator is implanted under the skin in the upper left or right area of the chest and connected to three leads that are implanted in the heart.

New Device Implanted On Heart Prevents Heart Failure
New device termed ‘Therepi’ can be attached directly to the damaged heart, allowing delivery of multiple treatment doses of stem cells to prevent heart failure following a heart attack.

‘Heart failure patients have limited treatment alternatives. But, a new device approved by the FDA can help treat heart failure patients who have no alternative treatment options.’
Read More..

After the device is implanted, a physician tests and programmes the device, which delivers electrical impulses to the heart during regular heartbeats to help improve the heart's squeezing capability.

The device would be beneficial for patients not suited to treatment with other heart failure devices such as cardiac resynchronization therapy to restore a normal timing pattern of the heartbeat, the US FDA noted in a statement.

"Patients with moderate-to-severe chronic heart failure have limited treatment options. And for those who are unable to be treated due to underlying conditions or who have not responded to available treatments, their quality of life may be impacted, with limits on the types of physical activities they can do," said Bram Zuckerman, Director at FDA's Centre for Devices and Radiological Health.

Genetic Risk of Heart Failure Highlighted in New Study
Familial risk of heart failure: There is limited understanding of genetic mechanisms leading to heart failure. Though the cardiomyopathies are fairly well documented, we need more studies on the heritability of heart failure. Understanding this will go a long way in improving public health.

"The FDA recognized the unmet need for these patients and worked with the manufacturer...to efficiently bring this product to market while ensuring it meets our regulatory requirements for safety and effectiveness," Zuckerman added.

For the study, the US FDA evaluated data from two clinical trials with a total of 389 patients with moderate-to-severe heart failure.

More Women Than Men Die Due To Heart Failure
Hospitalization rates as well as deaths due to heart failure have gone up in women, while there has been a decline of these in men, finds a recent study.

All patients received optimal medical therapy, and 191 patients also received an Optimizer Smart system implant.

The Optimizer Smart system improves the quality of life and functional status of certain heart failure patients.

Diabetes May Cause Heart Failure: Here�s Why
New study sheds light on how diabetes causes heart failure. Methylglyoxal (MG) is a glycolysis byproduct which is accelerated under diabetic conditions, modifies the cardiac myofilament more in diabetic heart failure patients.

The health body has granted approval of the Optimizer Smart system to US-based Impulse Dynamics.

Source-IANS